基于分子特征与疾病进展推进Still病的个体化精准治疗
本文为综述,讨论Still病(一种以多关节炎、高热、鲑色一过性皮疹和高铁蛋白血症为特征的系统性自身炎症性疾病)发病机制的最新进展及相应治疗策略。文章强调中性粒细胞和巨噬细胞在发病中的关键作用,并涉及自然杀伤细胞、T细胞和B细胞;细胞因子靶向生物制剂拓展了治疗选择,基于临床表现、并发症、免疫细胞和分子网络可开发相应生物制剂,免疫表型分型对精准临床亚型划分和靶向分子治疗至关重要。
要点
- Still病以多关节炎、高热、鲑色一过性皮疹和高铁蛋白血症为特征,具有经典的多基因背景。
- 中性粒细胞和巨噬细胞在Still病发病中起关键作用,自然杀伤细胞、T细胞和B细胞也参与其中。
- 细胞因子靶向生物制剂拓展了传统治疗之外的策略,部分可基于临床表现、并发症、免疫细胞和分子网络开发。
核心结论
- 强调基于免疫表型分型进行精准临床亚型划分,并据此开展靶向分子治疗,对优化治疗结局至关重要。
研究设计与样本
- 本文为综述,讨论Still病发病机制的最新进展及相应治疗策略。
主要发现
- Still病的确切病因仍不明确,被认为受遗传因素、感染和免疫失调影响。
- 中性粒细胞和巨噬细胞在Still病发病中起关键作用,自然杀伤细胞、T细胞和B细胞也参与其中。
- 生物制剂的进展使治疗策略超越传统方法,细胞因子靶向药物在Still病管理中显示出前景。
- 部分细胞因子靶向生物制剂可基于临床表现、并发症、免疫细胞和分子网络进行开发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Still's disease, a systemic autoinflammatory disorder with a classic multigenetic background, is characterised by polyarthritis, high-spiking fever, salmon-like evanescent skin rash, and hyperferritinaemia. Although the exact cause of Still's disease remains unclear, it is believed to be influenced by genetic factors, infections, and immune dysregulation. Current studies indicate that neutrophils and macrophages play crucial roles in the pathogenesis of Still's disease, along with involvement of natural killer cells, T cells, and B cells. Advances in biologic agents have expanded treatment strategies beyond conventional approaches, with cytokine-targeted agents showing promise in the management of Still's disease. Some cytokine-targeting biologic agents can be developed based on clinical manifestations, complications, immune cells, and molecular networks. Emphasis of immunophenotyping for precise clinical subtyping and targeted molecular therapies based on these findings is crucial for optimising treatment outcomes. In this Review, we discuss the latest advancements in the understanding of Still's disease pathogenesis and corresponding therapeutic approaches.
引用
- Shen Y, Jia J, Teng J, et al. Advancing personalised precision treatment for Still's disease based on molecular characteristics and disease progression. Lancet Rheumatol. 2024. PMID: 39433056. doi:10.1016/S2665-9913(24)00225-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。